title: [Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease].
abstract: The open 3-month study of influence of D2/D3 dopamine agonist pramipexole on of Parkinson's disease (PD) features, which are relatively resistant to traditional dopaminergic therapy: tremor, affective and cognitive impairment, has been conducted. Ninety-eight patients with PD, aged from 42 to 75 years (mean age 63,2+/-10,2 years), have been included in the study. Twenty percents of patients included were older than 70 years. The Hoehn and Yahr stage varied from 1 to 4 (men stage 2,5+/-0,8). Seventy percents of patients received levodopa (mean dosage 351,2+/-279,4 mg); 62% had motor fluctuations and 43% - dyskinesias. Pramipexole was titrated to effective dose (maximum 3 mg/d, mean 2,1 mg/d). The decrease of resting tremor by 50% and postural and kinetic tremor (assessed with the UPDRS and spiralography) by 37% was noticed to the end of 3 month. The severity of depressive symptoms measured with the Montgomery-Asberg scale and a modified version of the Geriatric Depression scale was reduced by one third. The statistically significant decrease of motor fluctuations and dyskinesias, increase of verbal fluency (but not other cognitive functions) were also found. The clinically significant effect of reducing of motor and non-motor symptoms was seen in 86% patients regardless of their age, illness duration, severity of motor deficit and affective and cognitive disturbances. The fair tolerability of the drug was shown including patients older than 70 years.
authors.forename: O S
authors.initials: OS
authors.lastname: Levin
authors.forename: O S
authors.initials: OS
authors.lastname: Nesterova
authors.forename: O V
authors.initials: OV
authors.lastname: Otcheskaia
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Zhuravleva
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Artemova
authors.forename: A A
authors.initials: AA
authors.lastname: Khozova
authors.forename: A M
authors.initials: AM
authors.lastname: Ismailov
authors.forename: L N
authors.initials: LN
authors.lastname: Lisenker
authors.forename: T V
authors.initials: TV
authors.lastname: Vdovichenko
authors.forename: L D
authors.initials: LD
authors.lastname: Rotor
authors.forename: P A
authors.initials: PA
authors.lastname: Ganzula
authors.forename: A K
authors.initials: AK
authors.lastname: Ivanov
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects* / Q000502:physiology; D000368:Aged; D052160:Benzothiazoles / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000077487:Pramipexole; D017448:Receptors, Dopamine D2 / Q000819:agonists; D016896:Treatment Outcome; D014202:Tremor / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D000077487:Pramipexole